Kate Johnson

News

Durvalumab Plus FLOT Ups Survival in Early Upper-GI Cancer

Author:: Kate Johnson

Publish date: October 23, 2025

The findings show that at 36 months, overall survival was 68.6% among patients who received durvalumab + FLOT vs 61.9% among those given FLOT plus ...

News

‘Cure’ in Cancer: Should Oncologists Use the Word?

Author:: Kate Johnson

Publish date: February 10, 2025

“What we know about that kind of anxiety is that there’s this cycle where reassurance doesn’t really help in the long term”.

News

Acalabrutinib Combo Promising as Frontline Treatment for CLL

Author:: Kate Johnson

Publish date: December 12, 2024

New research suggests that a BTK inhibitor combo boosts progression-free survival in patients with chronic lymphocytic leukemia.

News

Do GLP-1s Lower VTE Risk in People With Type 2 Diabetes?

Author:: Kate Johnson

Publish date: December 12, 2024

Taking GLP-1s lowers the risk of venous thromboembolism (VTE) in patients with type 2 diabetes, results of a retrospective study suggest.

News

POLARIX: Extended Results Confirm Standard of Care for DLBCL

Author:: Kate Johnson

Publish date: December 11, 2024

Updated research shows that a modified version of the R-CHOP regimen keeps outperforming R-CHOP in patients with diffuse large B-cell lymphoma.

News

24-Hour Urine Testing in Multiple Myeloma: Time to Stop?

Author:: Kate Johnson

Publish date: December 9, 2024

Fresh analysis shows that 24-hour urine testing in myeloma response assessments may safely be omitted without compromising accuracy.

News

IVIG Prophylaxis in Multiple Myeloma Cuts Infections, Boosts Survival

Author:: Kate Johnson

Publish date: December 9, 2024

New research suggests better outcomes during treatment with teclistamab for patients with myeloma who get intravenous immunoglobulin prophylaxis.

News

Vorasidenib for Certain IDH-Mutant Gliomas: Is It Worth It?

Author:: Kate Johnson

Publish date: December 2, 2024

Experts expressed concerns and doubts about the drug and the INDIGO trial, bringing a host of unanswered questions into sharper focus.

News

Neurologists Lack Awareness of Steroid Toxicity

Author:: Kate Johnson

Publish date: October 28, 2024

Over 85% of survey respondents indicated that a tool for systematically monitoring corticosteroid toxicity would be valuable.

News

Veterans Affairs Hailed as a ‘Bright Spot’ in ALS Care

Author:: Kate Johnson

Publish date: October 28, 2024

Transdisciplinary collaboration is essential for maintaining an effective system.

News

Digital Tool May Help Neurologists Assess Steroid Toxicity

Author:: Kate Johnson

Publish date: October 28, 2024

The study results “indicate that patients with MG who initiated steroids demonstrated evidence of steroid toxicity in as little as 90 days after in...

News

Remote Assessments: A Win-Win for ALS Patients and Clinics?

Author:: Kate Johnson

Publish date: October 24, 2024

Remote monitoring of patients with ALS is a feasible option for both maximizing quality of life and minimizing cost and disruption.

News

Sustained Control with Investigational Monoclonal Antibody for Myasthenia Gravis

Author:: Kate Johnson

Publish date: October 17, 2024

The VIVACITY-MG3 trial is the first registrational study of a neonatal fragment crystallizable receptor blocker to show sustained efficacy through ...

News

First-in-Class B-Cell Depleting Agent Promising for Myasthenia Gravis

Author:: Kate Johnson

Publish date: October 17, 2024

Although inebilizumab is already FDA-approved for the treatment of neuromyelitis optica, it still faces approval and indication hurdles for MG.

News

Antidepressants Linked to Improved Verbal Memory

Author:: Kate Johnson

Publish date: October 1, 2024

The clinical effect may be linked to changes in serotonin 4 (5-HT4) receptor levels in the brain.